Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
Journal of Cancer · 2025
Article
4 · The record
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 3 institutions in 1 country.
Anna FaragóAstridbio Technologies Ltd., Wimmer Fülöp utca 1, H6728 Szeged, Hungary.
Ágnes ZvaraInstitute of Genetics, Laboratory of Functional Genomics, HUN-REN Biological Research Centre, Temesvári krt. 62, H6726 Szeged, Hungary.
László TiszlaviczDepartment of Pathology, University of Szeged, Állomás u. 2, H6725 Szeged, Hungary.
Éva Hunyadi-GulyásCore Facility HUN-REN Biological Research Centre, Temesvári krt. 62, H6726 Szeged, Hungary.ORCID 0000-0003-2089-1499
Zsuzsanna DarulaCore Facility HUN-REN Biological Research Centre, Temesvári krt. 62, H6726 Szeged, Hungary.ORCID 0000-0003-1692-7591
Zoltán HegedűsCore Facility HUN-REN Biological Research Centre, Temesvári krt. 62, H6726 Szeged, Hungary.ORCID 0000-0001-9459-1654
Enikő SzabóInstitute of Genetics, Laboratory of Functional Genomics, HUN-REN Biological Research Centre, Temesvári krt. 62, H6726 Szeged, Hungary.
Sára Eszter SurgutaDepartment of Experimental Pharmacology, The National Tumor Biology Laboratory, National Institute of Oncology, Ráth György u. 7-9, H1122 Budapest, Hungary.
József TóváriDepartment of Experimental Pharmacology, The National Tumor Biology Laboratory, National Institute of Oncology, Ráth György u. 7-9, H1122 Budapest, Hungary.
László G PuskásInstitute of Genetics, Laboratory of Functional Genomics, HUN-REN Biological Research Centre, Temesvári krt. 62, H6726 Szeged, Hungary.
Gábor J SzebeniAstridbio Technologies Ltd., Wimmer Fülöp utca 1, H6728 Szeged, Hungary.ORCID 0000-0002-6998-5632
HUN-REN Szegedi Biológiai Kutatóközpont · HUUniversity of Szeged · HUNational Institute of Oncology · HU
Funding
Hungarian Scientific Research Fund grant K147410. Project no. 1018567Hungarian Thematic Excellence Programme TKP2021-EGA-44János Bolyai Research Scholarship of the Hungarian Academy of Sciences BO/00582/22/8KFI_16-1-2017-0105 National Research, Development, and Innovation Office (NKFI), HungaryNational Laboratories Excellence program 2022-2.1.1-NL-2022-00010National Research, Development, and Innovation Office 2020-1.1.6-JÖVŐ-2021-00003National Research, Development, and Innovation Office, Hungary 2022-1.2.6-TÉT-IPARI-TR-2022-00023National Research, Development, and Innovation Office (NKFI), Hungary 142877 FK22National Research, Development, and Innovation Office (NKFI), Hungary 2019-1.1.1-PIACI-KFI-2019-00444
6 · The paper itself
Abstract
A murine colorectal carcinoma (CRC) model was established. CT26 colon carcinoma cells were injected into BALB/c mice's spleen to study the primary tumor and the mechanisms of cell spread of colon cancer to the liver. The CRC was verified by the immunohistochemistry of Pan Cytokeratin and Vimentin expression. Immunophenotyping of leukocytes isolated from CRC-bearing BALB/c mice or healthy controls, such as CD19+ B cells, CD11+ myeloid cells, and CD3+ T cells, was carried out using fluorochrome-labeled lectins. The binding of six lectins to white blood cells, such as galectin-1 (Gal1), siglec-1 (Sig1),
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Lectin-Based Immunophenotyping and Whole Proteomic Profiling of CT-26 Colon Carcinoma Murine Model. · full record | OpenQuestion